# Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

> **NCT02779101** · PHASE2 · UNKNOWN · sponsor: **Prof. Dr. Matthias Preusser** · enrollment: 21 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT02779101
- **Lead sponsor:** Prof. Dr. Matthias Preusser
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2018-06
- **Final completion:** 2019-06
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2016-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779101, "Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02779101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*